Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Healthcare
Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada... see more

Recent & Breaking News (TSX:GUD)

IIROC Trade Halt - Knight Therapeutics Inc.

Newsfile December 3, 2014

Knight Therapeutics Inc. and CRH Medical Corporation Sign Secured Debt Financing Agreement

Marketwired December 2, 2014

Knight Sells Priority Review Voucher to Gilead

Marketwired November 19, 2014

Knight Reports Third Quarter 2014 Results

Marketwired November 12, 2014

Notice of Knight Therapeutics' Third Quarter 2014 Results Conference Call

Marketwired November 6, 2014

Knight Therapeutics Inc. Continues to Execute Its Innovative Pharmaceutical Product Sourcing Strategy

Marketwired October 28, 2014

Knight Therapeutics Inc. Expands Its Innovative Pharmaceutical Product Sourcing Strategy

Marketwired October 2, 2014

Knight Therapeutics Announces Receipts for Final Prospectuses and Conditional Approval for Listing on the Toronto Stock Exchange

Marketwired April 17, 2014

Knight Therapeutics Announces Receipts for Final Prospectuses and Conditional Approval for Listing on the Toronto Stock Exchange

Marketwired April 17, 2014

Medicure (V.MPH) snags industry expert advisor and investors smell acquisition, up 26%

Gaalen Engen April 15, 2014

Knight Therapeutics Completes Previously Announced "Bought Deal" Private Placement of Special Warrants for Gross Proceeds of Approximately $180 Million

Marketwired April 10, 2014

Knight Therapeutics Completes Previously Announced "Bought Deal" Private Placement of Special Warrants for Gross Proceeds of Approximately $180 Million

Marketwired April 10, 2014

Knight Therapeutics Announces Increase of Previously Announced "Bought Deal" Private Placement of Special Warrants to $180 Million

Marketwired March 21, 2014

Knight Therapeutics Enters into Agreement for a $75 Million "Bought Deal" Private Placement of Special Warrants

Marketwired March 21, 2014

Knight Therapeutics (V.GUD) obtains US FDA approval for Impavido(R), up 9%

Gaalen Engen March 20, 2014

Knight Therapeutics Inc. Announces FDA Approval for Impavido(R) (Miltefosine) for the Treatment of Visceral, Mucosal and Cutaneous Leishmaniasis

Marketwired March 19, 2014

Knight Therapeutics Completes Previously Announced "Bought Deal" Private Placement of Special Warrants for Gross Proceeds of Approximately $75 Million

Marketwired March 19, 2014

Knight Therapeutics Announces Over-Allotment Option in Previously Announced "Bought Deal" Private Placement of Special Warrants, Bringing Expected Proceeds to $75 Million

Marketwired March 6, 2014

Knight Therapeutics Enters Into Agreement for a $71 Million "Bought Deal" Private Placement of Special Warrants

Marketwired March 5, 2014

IIROC Trading Resumption - GUD

Canada NewsWire February 28, 2014